August 27, 2020
A Phase 1 patient trial of the novel, oral therapy candidate, alpha-TEA, for advanced HER2 positive breast cancer is now underway. Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin. In HER2 positive […]